ProLynx Publishes Results Of Ultralong Half-Life PEG-SN38 Pro-Drug With Lower Intestinal Toxicity
3/28/2014 8:30:32 AM
SAN FRANCISCO, March 27, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC today announced a publication in the Journal of Medicinal Chemistry on macromolecular pro-drugs that provide the irinotecan active-metabolite SN-38 with ultralong half-life, low Cmax, and low glucuronide formation. These macromolecular pro-drugs have unique pharmacokinetic profiles that may translate to less intestinal toxicity and interpatient variability than the SN-38 pro-drugs thus far studied.
Help employers find you! Check out all the jobs and post your resume.
comments powered by